Phase 1 trial of HS-10504 shows encouraging responses in EGFR C797S mutant lung cancer

HS-10504, an investigational therapy, was evaluated in a Phase 1 study in patients with non-small cell lung cancer harboring the EGFR C797S mutation after progression on prior tyrosine kinase inhibitors.

The trial reported objective responses in a subset of participants, indicating the drug can overcome resistance associated with the C797S alteration.

Safety was described as manageable, with most adverse events being low grade, supporting further clinical development.